Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
or

Heron Therapeutics (HRTX)

Heron Therapeutics (HRTX)
1.7600 x 1 1.8900 x 1
Post-market by (Cboe BZX)
1.7700 +0.0400 (+2.31%) 02/24/25 [NASDAQ]
1.7600 x 1 1.8900 x 1
Post-market 1.7500 -0.0200 (-1.13%) 18:01 ET
Quote Overview for Mon, Feb 24th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.6900
Day High
1.8000
Open 1.7300
Previous Close 1.7300 1.7300
Volume 984,400 984,400
Avg Vol 1,160,525 1,160,525
Stochastic %K 45.18% 45.18%
Weighted Alpha -22.85 -22.85
5-Day Change -0.0100 (-0.56%) -0.0100 (-0.56%)
52-Week Range 1.0400 - 3.9300 1.0400 - 3.9300
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 263,124
  • Shares Outstanding, K 152,095
  • Annual Sales, $ 127,040 K
  • Annual Income, $ -110,560 K
  • EBIT $ -26 M
  • EBITDA $ -24 M
  • 60-Month Beta 1.60
  • Price/Sales 1.90
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 110.49% ( -1.42%)
  • Historical Volatility 56.96%
  • IV Percentile 70%
  • IV Rank 40.56%
  • IV High 244.27% on 02/03/25
  • IV Low 19.22% on 09/09/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 3
  • Volume Avg (30-Day) 188
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 7,510
  • Open Int (30-Day) 7,492

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.03
  • Number of Estimates 2
  • High Estimate -0.03
  • Low Estimate -0.03
  • Prior Year -0.07
  • Growth Rate Est. (year over year) +57.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.6000 +10.62%
on 02/12/25
Period Open: 1.8300
1.9200 -7.81%
on 01/27/25
-0.0600 (-3.28%)
since 01/24/25
3-Month
1.0700 +65.42%
on 11/26/24
Period Open: 1.0700
1.9900 -11.06%
on 12/04/24
+0.7000 (+65.42%)
since 11/22/24
52-Week
1.0400 +70.19%
on 11/12/24
Period Open: 2.6000
3.9300 -54.96%
on 06/12/24
-0.8300 (-31.92%)
since 02/23/24

Most Recent Stories

More News
Heron Therapeutics: Q3 Earnings Snapshot

Heron Therapeutics: Q3 Earnings Snapshot

HRTX : 1.7700 (+2.31%)
Heron Therapeutics: Q2 Earnings Snapshot

Heron Therapeutics: Q2 Earnings Snapshot

HRTX : 1.7700 (+2.31%)
Heron Therapeutics: Q1 Earnings Snapshot

Heron Therapeutics: Q1 Earnings Snapshot

HRTX : 1.7700 (+2.31%)
Heron Therapeutics: Q4 Earnings Snapshot

Heron Therapeutics: Q4 Earnings Snapshot

HRTX : 1.7700 (+2.31%)
Heron Therapeutics: Q3 Earnings Snapshot

Heron Therapeutics: Q3 Earnings Snapshot

HRTX : 1.7700 (+2.31%)
Heron Therapeutics: Q2 Earnings Snapshot

Heron Therapeutics: Q2 Earnings Snapshot

HRTX : 1.7700 (+2.31%)
Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates

/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company focused on improving the lives of...

HRTX : 1.7700 (+2.31%)
Heron Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023

/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and...

HRTX : 1.7700 (+2.31%)
Heron Therapeutics Announces Cost Reduction Plan and Restructuring

/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and...

HRTX : 1.7700 (+2.31%)
Heron Therapeutics Announces Appointment of Ira Duarte as Chief Financial Officer

/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing...

HRTX : 1.7700 (+2.31%)

Business Summary

Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting....

See More

Key Turning Points

3rd Resistance Point 1.9256
2nd Resistance Point 1.8628
1st Resistance Point 1.8164
Last Price 1.7700
1st Support Level 1.7072
2nd Support Level 1.6444
3rd Support Level 1.5980

See More

52-Week High 3.9300
Fibonacci 61.8% 2.8260
Fibonacci 50% 2.4850
Fibonacci 38.2% 2.1440
Last Price 1.7700
52-Week Low 1.0400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Mastering Fibonacci: The Hidden Order in Market Movements